Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest update is out from Avalon GloboCare ( (ALBT) ).
On February 18, 2025, Avalon GloboCare Corp. announced it received a Notice of Allowance from the China National Intellectual Property Administration for its patent application AVAR1901CN. This patent, co-developed with Arbele Limited, is a significant milestone in CAR-T and CAR-NK cell technology, enhancing Avalon’s global intellectual property footprint. The patented technology’s key features include a bispecific anti-CD19xCD22 CAR, which targets both CD19 and CD22 antigens, reducing the risk of tumor escape due to antigen loss, and localized cytokine induction to improve CAR cell efficacy. This development strengthens Avalon’s position in the global market and aims to improve accessibility and outcomes for patients worldwide.
More about Avalon GloboCare
Avalon GloboCare Corp. is a commercial stage company focused on developing and delivering innovative precision diagnostics and clinical laboratory services. The company provides a wide range of diagnostic tests, including drug testing, toxicology, general bloodwork, anatomic pathology, and urine toxicology, utilizing proprietary technology to deliver precise, genetics-driven results.
YTD Price Performance: 7.58%
Average Trading Volume: 906,684
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $4.04M
For a thorough assessment of ALBT stock, go to TipRanks’ Stock Analysis page.
